Skip to main
XAIR

XAIR Stock Forecast & Price Target

XAIR Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Beyond Air is a promising medical device and biopharmaceutical company led by new CEO Robert Goodman, who is focused on accelerating the adoption of the company's LungFit PH product, expanding international operations, and achieving revenue generation. Early data for their Beyond Cancer treatment shows promising results, and while the termination of a previous agreement presents some financial risks, the company remains committed to maximizing value for their NeuroNOS asset through alternative partnerships. The company also faces potential risks in the areas of clinical development, third-party dependency, intellectual property, and operational and employee issues.

Bears say

Beyond Air is currently undergoing a leadership change and bringing in a new Chief Commercial Officer, indicating a focus on driving sales and expanding market adoption for its nitric oxide platform. With a strong background in commercial operations, the new CCO, Mr. Goodman, is expected to accelerate the company's business strategy and push for increased utilization in the US and improved execution internationally. This focus on the commercial aspects of the business is critical as Beyond Air continues to prioritize its current primary driver, the LungFit PH system, and pursue additional pulmonary indications, while also maintaining the longer-term potential of its NeuroNOS platform.

XAIR has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beyond Air Inc (XAIR) Forecast

Analysts have given XAIR a Strong Buy based on their latest research and market trends.

According to 1 analysts, XAIR has a Strong Buy consensus rating as of Jun 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beyond Air Inc (XAIR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.